Cyclica company

Cyclica is a biotechnology company that leverages AI and computational biophysics to decentralize drug discovery. The company approaches polypharmacology with a structure-based, AI-augmented in silico discovery platform, centred on Ligand Design and Ligand Express. Powered by MatchMaker™, a proprietary deep learning proteome screening technology, and POEM™, an innovative supervised learning technology for predicting molecular properties, Cyclica’s platform is suited to the design of novel, drug-like chemical matter by simultaneously prioritizing compounds based on their on- and off-target polypharmacological profiles as well as their developmental properties. With a team that has deep roots in the industry, a platform, and an innovative decentralized partnership model, Cyclica is creating medicines with precision for unmet patient needs. Jason Mitakidis and Naheed Kurji founded the biotech company in Toronto, Ontario in 2013.
Technology: NeuroTech
Industry: Artificial Intelligence, Biotechnology, Data and Analytics, Health Care, Science and Engineering, Software
Headquarters: Toronto, Ontario, Canada
Founded Date: 2013-05-01
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 1
Total Funding: CA$7.4M
Estimated Revenue: $1M to $10M
Last Funding Type: Seed

Visit Website
Register and Claim Ownership